Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Annette M, Chang"'
Publikováno v:
Diabetes Therapy. 14:883-897
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a5383da9181ce1b07e40454cc53daf71
https://doi.org/10.1007/s13300-023-01400-w
https://doi.org/10.1007/s13300-023-01400-w
Publikováno v:
Diabetes therapy : research, treatment and education of diabetes and related disorders. 13(8)
Ultra-rapid lispro (URLi) is a new prandial insulin lispro formulation. In the PRONTO-T2D study, URLi, in a basal-bolus regimen with glargine or degludec, was non-inferior to lispro (HumalogPRONTO-T2D was a phase 3, 26-week, double-blind, treat-to-ta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6f1c3e2b8b55e884723a9c93563c8ab
https://pubmed.ncbi.nlm.nih.gov/35781789
https://pubmed.ncbi.nlm.nih.gov/35781789
Autor:
Angela Subauste, Roberto Gianani, Annette M Chang, Cynthia Plunkett, Susan L Pietropaolo, Ying-Jian Zhang, Emma Barinas-Mitchell, Lewis H Kuller, Andrzej Galecki, Jeffrey B Halter, Massimo Pietropaolo
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e106537 (2014)
There is a paucity of literature describing metabolic and histological data in adult-onset autoimmune diabetes. This subgroup of diabetes mellitus affects at least 5% of clinically diagnosed type 2 diabetic patients (T2DM) and it is termed Latent Aut
Externí odkaz:
https://doaj.org/article/acf064debaab47c4acfb1cf4f1bdcab2
Publikováno v:
Diabetes. 69
URLi is a novel prandial insulin lispro formulation developed to more closely match physiological insulin secretion. PRONTO-T2D, a Phase 3, double-blind, treat-to-target study in pts with T2D, showed URLi, in a basal-bolus regimen with glargine or de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::753960dd08b4d2265dc6f3e9c1005fd9
https://doi.org/10.2337/db20-1046-p
https://doi.org/10.2337/db20-1046-p
Autor:
Hideaki Jinnouchi, Annette M. Chang, Qianyi Zhang, Thomas Blevins, Juan P. Frias, Pronto-T D Investigators
Publikováno v:
Diabetes Care
OBJECTIVE To evaluate the efficacy and safety of ultra rapid lispro (URLi) versus lispro in patients with type 2 diabetes on a basal-bolus insulin regimen. RESEARCH DESIGN AND METHODS This was a phase 3, treat-to-target, double-blind 26-week study. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a022a1d5d7cdb0937ba1a867030c2542
https://pubmed.ncbi.nlm.nih.gov/32616612
https://pubmed.ncbi.nlm.nih.gov/32616612
Autor:
Junxiang Luo, Yongming Qu, Scott J. Jacober, Parag Garhyan, Annette M. Chang, Caryl J. Antalis
Publikováno v:
Journal of Diabetes Science and Technology. 12:155-162
For new insulin analogs with properties that vary from human insulin, defining activity in units of human insulin based on glycemic lowering efficacy may be challenging. Here we present a new method that can be used to quantify a unit dose of an expe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e68cb857d127cf1b64bcd2f33a4764f
https://doi.org/10.1177/1932296817707542
https://doi.org/10.1177/1932296817707542
Publikováno v:
Diabetes. 68
URLi is a novel prandial insulin lispro formulation developed to more closely match physiological insulin secretion. This phase 3, multicenter, treat-to-target, 26-week trial evaluated the efficacy and safety of URLi vs. lispro in patients with T2D.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a253fa5627618494dbe669be8ab6cb38
https://doi.org/10.2337/db19-145-or
https://doi.org/10.2337/db19-145-or
Autor:
A. N. Higdon, Shuyu Zhang, Juliana M. Bue-Valleskey, Scott J. Jacober, Edward J. Bastyr, Arun J. Sanyal, Axel Haupt, Annette M. Chang, Mark L. Hartman, Byron J. Hoogwerf, Kenneth Cusi
Publikováno v:
Diabetes, Obesity and Metabolism. 18:50-58
AIMS To compare effects of basal insulin peglispro (BIL), a hepatopreferential insulin, to insulin glargine (glargine) on aminotransferases and liver fat content (LFC) in patients with type 1 and type 2 diabetes (T1D, T2D). MATERIALS AND METHODS Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91e26f63cf371dadb27ba8e46ea73dc1
https://doi.org/10.1111/dom.12751
https://doi.org/10.1111/dom.12751
Autor:
Melvin J. Prince, Annette M. Chang, Yongming Qu, Shuyu Zhang, Julio Rosenstock, Edward J. Bastyr, Michel Marre
Publikováno v:
Diabetes, Obesity & Metabolism
Basal insulin peglispro (BIL) is a novel basal insulin with hepato-preferential action, resulting from reduced peripheral effects. This report summarizes hypoglycaemia data from five BIL phase III studies with insulin glargine as the comparator, incl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf2d286b1cb0a0d028876a7eb402840
http://europepmc.org/articles/PMC5096011
http://europepmc.org/articles/PMC5096011
